Pulmonary Hypertension – Unmet Need – Detailed, Expanded Analysis (US & EU)
Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder marked by considerable morbidity and mortality. Despite the availability of a wide array of drugs for PAH, substantial unmet need remains for more-effective, more-tolerable agents. Based on our survey results and physician interviews, we discuss the relative attractiveness of various drug attributes and the implications for PAH drug development. In our conjoint analysis, we reveal the key trade-offs that surveyed cardiologists and pulmonologists are willing to make when considering new treatment options for PAH. Understanding the influence of key efficacy, safety / tolerability, and nonclinical attributes on physicians’ prescribing behavior can pave the way to commercial success in this competitive landscape.
QUESTIONS ANSWERED
- What are the key treatment drivers and goals within PAH? How do the current therapies perform on these goals?
- What attributes drive decision-making when treating PAH patients, which have limited impact, and which are hidden opportunities?
- Based on a conjoint analysis and TPP simulation, what trade-offs across different clinical attributes and prices are acceptable to U.S. and European cardiologists and pulmonologists for a hypothetical PAH drug?
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 61 U.S. and 31 European cardiologists and pulmonologists fielded in March 2022.
Key drugs: Adempas, Uptravi, Opsumit, Remodulin / epoprostenol, Tyvaso / Ventavis, Orenitram, tadalafil.
Table of contents
- Pulmonary Hypertension - Unmet Need - Detailed, Expanded Analysis (US & EU)
- Unmet need - Pulmonary arterial hypertension - TPP Simulator - June 2022
- Executive summary
- Introduction
- Treatment drivers and goals
- Key findings: attribute importance
- Relative importance of efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to surveyed cardiologists' / pulmonologists' prescribing decisions in pulmonary arterial hypertension
- Importance of efficacy attributes to prescribing decisions in pulmonary arterial hypertension: United States
- Importance of efficacy attributes to prescribing decisions in pulmonary arterial hypertension: Europe
- Importance of safety and tolerability attributes to prescribing decisions in pulmonary arterial hypertension: United States
- Importance of safety and tolerability attributes to prescribing decisions in pulmonary arterial hypertension: Europe
- Importance of convenience of administration attributes to prescribing decisions in pulmonary arterial hypertension: United States
- Importance of convenience of administration attributes to prescribing decisions in pulmonary arterial hypertension: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in pulmonary arterial hypertension: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in pulmonary arterial hypertension: Europe
- Product performance against treatment drivers and goals
- Key findings
- Overall performance of key therapies for pulmonary arterial hypertension: United States
- Overall performance of key therapies for pulmonary arterial hypertension: Europe
- Mean overall performance of key therapies for pulmonary arterial hypertension: United States and Europe
- Relative performance of key therapies for pulmonary arterial hypertension across select efficacy attributes: United States
- Relative performance of key therapies for pulmonary arterial hypertension across select efficacy attributes: Europe
- Relative performance of key therapies for pulmonary arterial hypertension across select safety and tolerability attributes: United States
- Relative performance of key therapies for pulmonary arterial hypertension across select safety and tolerability attributes: Europe
- Relative performance of key therapies for pulmonary arterial hypertension across select convenience of administration attributes: United States
- Relative performance of key therapies for pulmonary arterial hypertension across select convenience of administration attributes: Europe
- Assessment of unmet need
- Key findings: unmet need in pulmonary arterial hypertension
- Surveyed pulmonologists' / cardiologistsu2019 satisfaction with the performance of key therapies on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: United States
- Surveyed pulmonologists' / cardiologistsu2019 satisfaction with the performance of key therapies for pulmonary arterial hypertension on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed pulmonologists' / cardiologistsu2019 ascribed level of unmet need across key efficacy attributes in pulmonary arterial hypertension: United States
- Surveyed pulmonologists' / cardiologistsu2019 ascribed level of unmet need across key efficacy attributes in pulmonary arterial hypertension: Europe
- Surveyed pulmonologists' / cardiologistsu2019 ascribed level of unmet need across key safety and tolerability attributes in pulmonary arterial hypertension: United States
- Surveyed pulmonologists' / cardiologistsu2019 ascribed level of unmet need across key safety and tolerability attributes in pulmonary arterial hypertension: Europe
- Surveyed pulmonologists' / cardiologistsu2019 ascribed level of unmet need across key convenience of administration attributes in pulmonary arterial hypertension: United States
- Surveyed pulmonologists' / cardiologistsu2019 ascribed level of unmet need across key convenience of administration attributes in pulmonary arterial hypertension: Europe
- Key findings: unmet need in pulmonary arterial hypertension and related indications
- Surveyed pulmonologists' / cardiologists' ascribed level of unmet need in pulmonary arterial hypertension and related indications: United States
- Surveyed pulmonologists' / cardiologists' ascribed level of unmet need in pulmonary arterial hypertension and related indications: Europe
- Opportunity analysis
- Target product profiles
- Appendix
Yogesh Shelke, M.B.A. (Pharm.), is an associate manager on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at Clarivate. Before joining Clarivate, he was instrumental in providing actionable insights to clients from various leading pharmaceutical companies regarding competitive intelligence, market sizing and forecasting, pipeline analysis, situational analysis, unmet need analysis, and market entry strategies in a variety of therapeutic areas. He holds a bachelor’s degree in pharmacy from Pune University and a master’s degree in pharmaceutical marketing from the National Institute of Pharmaceutical Education and Research in Mohali, India.